Exelixis (EXEL) Change in Account Payables (2016 - 2026)
Exelixis (EXEL) recorded quarterly Change in Account Payables of -$17.9 million in Q2 2026, down 38.74% quarter-over-quarter from -$12.9 million in Q1 2026, and down 310.53% on a YoY basis from $8.5 million in Q2 2025.
Exelixis (EXEL) Change in Account Payables (2016 - 2026) Analysis & Trends
Exelixis' Change in Account Payables history runs 11 years deep, the most recent figure standing at -$17.9 million for Q2 2026.
- In Q2 2026, Change in Account Payables fell 310.53% year-over-year to -$17.9 million; the TTM figure through Apr 2026 stood at -$76.6 million (down 466.94% YoY), while the FY2026 annual figure was -$50.2 million, down 129.15% from the prior year.
- Change in Account Payables was -$17.9 million for Q2 2026 at Exelixis, down from -$12.9 million in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $43.6 million in Q4 2023 to a low of -$63.5 million in Q3 2025.
- Historically, Change in Account Payables has averaged -$968823.5 across 5 years, with a median of $2.2 million in 2025.
- Biggest YoY gain for Change in Account Payables was 3481.14% in 2024; the steepest drop was 8332.45% in 2024.
- A 5-year view of Change in Account Payables shows it stood at $19.8 million in 2022, then jumped by 120.68% to $43.6 million in 2023, then plunged by 39.52% to $26.4 million in 2024, then tumbled by 32.73% to $17.8 million in 2025, then tumbled by 200.8% to -$17.9 million in 2026.
- The last three Change in Account Payables figures came in at -$17.9 million (Q2 2026), -$12.9 million (Q1 2026), and $17.8 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -9.42 Mn |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | -17.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | -17.90 Mn |
| Apr 3, 2026 | -17.90 Mn |
| Jan 2, 2026 | -12.90 Mn |
| Jan 2, 2026 | -12.90 Mn |
| Oct 3, 2025 | 17.76 Mn |
| Oct 3, 2025 | 17.76 Mn |
| Jul 4, 2025 | -63.51 Mn |
| Jul 4, 2025 | -63.51 Mn |
| Apr 4, 2025 | 8.50 Mn |
| Apr 4, 2025 | 8.50 Mn |
| Jan 3, 2025 | 2.24 Mn |
| Jan 3, 2025 | 2.24 Mn |
| Sep 27, 2024 | 26.39 Mn |
| Sep 27, 2024 | 26.39 Mn |
| Jun 28, 2024 | -16.28 Mn |
| Jun 28, 2024 | -16.28 Mn |
| Mar 29, 2024 | -34.25 Mn |
| Mar 29, 2024 | -34.25 Mn |
| Dec 29, 2023 | 43.64 Mn |
| Dec 29, 2023 | 43.64 Mn |